Skip to content
TrialScanner

NCT03315143

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Phase 3TerminatedLXRXLeadSNYCollaborator

Registry record

Lead sponsor
Lexicon Pharmaceuticals
Conditions
Heart Failure; Type 2 Diabetes Mellitus; Chronic Kidney Diseases
Primary completion
Jul 8, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03315143 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03315143: Effect of Sotagliflozin on... | TrialScanner